Finanzas y Negocios
¿Mi trabajo me puede enfermar?
Ver más
Políticas Médicas
Las políticas médicas son documentos que definen el reconocimiento de cubierta para tecnologías, procedimientos y tratamientos. Las declaraciones de necesidad médica en las políticas, sobre si una tecnología, procedimiento, tratamiento, suplido, equipo, medicamento u otro servicio mejora el resultado en la salud de la población para la cual dicha tecnología o tratamiento fue diseñado se basan en evidencia científica, estudios clínicos y opiniones profesionales de nuestros proveedores y de las organizaciones médicas reconocidas.
Cada documento desplegado en este sitio Web se provee con propósitos informativos solamente y no es una autorización, explicación de beneficios o un contrato. El recibir beneficios está sujeto a la satisfacción de todos los términos y condiciones de la cubierta. La tecnología médica cambia constantemente y nos reservamos el derecho de revisar y actualizar nuestras políticas periódicamente.
| ID | Título | Última Revisión | Siguiente Revisión | Descripción | Acceso |
|---|---|---|---|---|---|
| 11.003.079 | Invasive Prenatal (Fetal) Diagnostic Testing | Sep 07, 2023 | Sep 20, 2024 | Chromosomal microarray testing in patients who are undergoing invasive diagnostic prenatal (fetal)... | Ver |
| 11.003.081 | Genetic Testing for Macular Degeneration | Apr 18, 2024 | Apr 20, 2025 | Genetic testing for macular degeneration is considered... | Ver |
| 11.003.082 | Genetic Testing for Facioscapulohumeral Muscular Dystrophy | Mar 15, 2024 | Mar 20, 2025 | Genetic testing for facioscapulohumeral muscular dystrophy may be considered medically necessary to confirm... | Ver |
| 11.003.083 | Genetic Testing for CHARGE Syndrome | Mar 15, 2024 | Mar 20, 2025 | Genetic testing for charge syndrome may be considered medically necessary to confirm a diagnosis in a... | Ver |
| 11.003.084 | Genetic Testing for Idiopathic Dilated Cardiomyopathy | Mar 15, 2024 | Mar 20, 2025 | Comprehensive genetic testing for individuals with signs or symptoms of dilated cardiomyopathy, which is... | Ver |
| 11.003.085 | Genetic Testing for Limb-Girdle Muscular Dystrophies | Jun 18, 2024 | Policy Archived | Genetic testing for genes associated with limb-girdle muscular dystrophy to confirm a diagnosis of... | Ver |
| 11.003.086 | KIF6 Genotyping for Predicting Cardiovascular Risk | Aug 20, 2021 | Policy Archived | Kif6 genotyping is considered investigational for predicting cardiovascular risk and/or the effectiveness of... | Ver |
| 11.003.087 | Molecular Testing in the Management of Pulmonary Nodules | Jun 18, 2024 | Jun 20, 2025 | Plasma-based proteomic screening, including but not limited to nodify xl2® (bdx-xl2), nodify cdt®, and... | Ver |
| 11.003.088 | Molecular Testing for Chronic Heart Failure and Heart Transplant | Jun 17, 2021 | Policy Archived | The use of the presage st2 assay to evaluate the prognosis of patients diagnosed with chronic heart failure... | Ver |
| 11.003.089 | Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsy) | Sep 19, 2023 | Sep 20, 2024 | The use of circulating tumor dna and/or circulating tumor cells is considered investigational for all... | Ver |
| 11.003.090 | RATIONALE | Apr 15, 2024 | Apr 20, 2025 | Gene expression profiling for uveal melanoma with decisiondx-um is medically necessary for patients with... | Ver |
| 11.003.092 | Proteogenomic Testing for Patients With Cancer | Jul 08, 2024 | Jul 20, 2025 | Proteogenomic testing (see policy guidelines section) of individuals with cancer (including, but not limited... | Ver |
| 11.003.093 | Genetic Testing for Mitochondrial Disorders | Oct 12, 2023 | Oct 20, 2024 | Genetic testing to establish a genetic diagnosis of a mitochondrial disorder may be considered medically... | Ver |
| 11.003.094 | Serum Biomarker Panel Testing for Systemic Lupus Erythematosus and Other Connective Tissue Diseases | Jul 08, 2024 | Jul 20, 2025 | Serum biomarker panel testing with proprietary algorithms and/or index scores for the diagnosis of systemic... | Ver |
| 11.003.095 | Genotype-Guided Tamoxifen Treatment | Aug 11, 2023 | Aug 20, 2024 | Genotyping to determine cytochrome p450 2d6 (cyp2d6) variants is considered investigational for the purpose... | Ver |
| 11.003.096 | Miscellaneous Genetic and Molecular Diagnostic Tests | Aug 11, 2023 | Aug 20, 2024 | All tests listed in this policy are considered investigational and grouped according to the categories of... | Ver |
| 11.003.097 | Gene Expression Profiling for Cutaneous Melanoma | Jun 07, 2024 | Jun 20, 2025 | Gene expression testing, including but not limited to the pigmented lesion assay, in the evaluation of... | Ver |
| 11.003.098 | Use of Common Genetic Variants (Single Nucleotide Variants) to Predict Risk of Nonfamilial Breast Cancer | Nov 16, 2023 | Nov 20, 2024 | Testing for 1 or more single nucleotide variants to predict an individual’s risk of breast cancer is... | Ver |
| 11.003.099 | Circulating Tumor DNA for Management of Non-Small-Cell Lung Cancer (Liquid Biopsy) | Dec 10, 2021 | Policy Archived | The use of proteomic testing, including but not limited to the veristrat assay, is considered investigational... | Ver |
| 11.003.100 | DNA-Based Testing for Adolescent Idiopathic Scoliosis | Mar 05, 2021 | Policy Archived | Dna-based prognostic testing for adolescent idiopathic scoliosis is... | Ver |
